# **Synthesis, crystal structure and molecular orbital investigation of the first platinum complex of piroxicam**  $\dagger$

#### **Renzo Cini** \*

*Dipartimento di Chimica, Universita di Siena, Pian dei Mantellini 44, 1-53100 Siena, Italy* 

The first platinum complex  $[PLC]$ <sub>1</sub>(dmso)(HL)] of the widely used anti-inflammatory drug piroxicam (HL = 4hydroxy-2-methyl-N-( 2-pyridyl)-2H- **1,2-benzothiazine-3-carboxamide 1,** 1 -dioxide; dmso = dimethyl sulfoxide) was obtained from  $K<sub>2</sub>[PtCl<sub>4</sub>]$ . Its crystal structure reveals that the metal atom is linked to the pyridyl nitrogen atom. A  $Pt \cdots H-N$  (amide) interaction is present and made possible by the orientation of the HL molecule which brings the N(amide)-H bond above the co-ordination plane and almost parallel to the N (pyridyl)-Pt vector. The amide hydrogen was located from the Fourier-difference-synthesis and its position refined. The Pt  $\cdots$  H distance is 2.35 Å (0.25–0.55 Å shorter than the sum of the van der Waals radii), whereas the v(N-H) vibration band is red-shifted by about 90 cm<sup>-1</sup> upon complexation. An extended-Hückel molecular orbital analysis revealed that a mixing of  $d_{\gamma}(\mathbf{Pt})$  and  $p_{\gamma}[\mathbf{N}(\text{amide})]$  atomic orbitals occurs, whereas electrostatic Pt  $\cdots$  H attractive forces can play a significant role.

Interest in neutral complexes of platinum $(II)$  arises from the high anticancer activity of cis- $[Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>]$  (cisplatin) and related species. However, the antineoplastic activity of platinum(I1) compounds is not restricted to cisplatin-type complexes and the preparation of new compounds is important to investigate potential activities, better to understand the structure-activity relationship, and to shed light on the drugbiosystem interaction. '

Piroxicam[4-hydroxy-2-methyl- $N-(2$ -pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,l-dioxide; feldene, Pfizer] is an extensively used anti-inflammatory, anti-arthritic drug of the carboxamide family (Scheme 1). The drug, which has a variety of possible donor sites such as  $N(1')$ ,  $N(2)$ ,  $O(17)$ ,  $O(15)$ , may act as a monodentate and/or chelating agent, and its ligating ability towards some first-row transition-metal and zinc(I1) and cadmium( $I1$ ) ions has recently been investigated.<sup>2</sup> The oxygenradical-scavenger activity of the copper(I1) derivative has also been studied.<sup>3</sup> The structural investigation of metal-piroxicam complexes is important to analyse both the ligating ability of the drug and the effects of co-ordination on the conformation of the HL/L<sup>-</sup> molecules. Complexes [PtX<sub>2</sub>(L')(HL)] (X = halide,  $L' =$  easily removable ligand) can be of interest both for the potential anticancer activity derived from the  $PtX_2$ function or from the metal-linked HL moiety *(e.g. via* platinumand/or HL-nucleic acid interaction), and for anti-inflammatory tests. Furthermore, weak forces as those of the  $Pt^{\text{II}} \cdots Pt^{\text{II}}$  and  $Pt<sup>H</sup> \cdots H(N/C)$  type and hydrogen bonds are important for the stability of a number of compounds **43** and help to understand the activation of H-N and H-C bonds.<sup>5</sup>

Here **I** report on the synthesis and structural characterization of  $[PtCl<sub>2</sub>(dmso)(HL)]$  (dmso = dimethyl sulfoxide) which is the first complex of piroxicam with any of the third series of d-block elements to be analysed *via* X-ray diffraction.

# **Experimental**

# **Materials**

Piroxicam was a gift from Pfizer Italia spa;  $K_2[PtCl_4]$  was obtained from Janssen (Belgium), dimethyl sulfoxide, *n*butanol and PhCl from Merck (Germany).



**Scheme 1** Neutral piroxicam HL in the *4,16-EZE* conformation

#### **Preparation of** *trans-* [ **PtCl,(dmso)(HL)]**

A mixture of  $K_2[PtCl_4]$  (200 mg, 0.48 mmol) and dmso (4 cm<sup>3</sup>) was stirred at room temperature for about 0.5 h. The white precipitate (KC1) was filtered off, and the yellow filtrate added to a solution of  $HL$  (166 mg, 0.5 mmol) in dmso  $(4 \text{ cm}^3)$ . The mixture was stirred at 110 °C for 0.5 h (it turned orange) and then Bu<sup>n</sup>OH (35 cm<sup>3</sup>, 110 °C) slowly added. A fine pale yellow crystalline solid formed. The final suspension was left to cool to room temperature. The solid was filtered off and washed with a small amount of dmso, Bu"0H (twice) and diethyl ether, and finally dried under vacuum at 40 °C for 24 h. Yield *ca.* 50% (Found: C, 30.60; H, 2.90; C1, 10.1; N, 6.50; Pt, 28.1; **S,** 9.30. Calc. for  $C_1$ , H<sub>19</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>5</sub>PtS<sub>2</sub>: C, 30.25; H, 2.85; Cl, 10.50; N, 6.20; Pt, 28.90; **S,** 9.50%). The complex is insoluble in all of the common solvents tested and is just slightly soluble in dmso and hot chlorobenzene. Single crystals (yellow) suitable for X-ray diffraction were obtained from a solution prepared by dissolving the microcrystalline compound (10 mg) in chlorobenzene  $(40 \text{ cm}^3)$  at reflux.

#### **Crystal-structure determination**

~~ ~ \_\_\_\_~~~~~ ~ \_\_\_\_~~ A well formed prism (0.25  $\times$  0.35  $\times$  0.35 mm) was selected and mounted on a glass fibre for the X-ray data collection, which was carried out on a Siemens P4 automatic diffractometer operating at 22 "C. Crystallographic data are reported in Table 1. Unit-cell parameters were obtained by least-squares refinement of the values of 25 carefully centred and randomly selected reflections (20 10-30°). The intensities were corrected for Lorentz, polarization and absorption effects (y-scan for Lorentz, polarization and absorption effects ( $\psi$ -scan technique based on the reflections  $-1$  1 3, 3  $-1$   $-4$  and 6 0 technique based on the reflections  $-1$  1 3, 3  $-1$   $-4$  and 6 0<br>-14). The structure solution and refinement (space group,  $P2_1/c$ , - 14). The structure solution and refinement (space group,  $P2_1/c$ , no. 14, from systematic absences; mean  $|E^2 - 1| = 0.925, 0.968$ for centrosymmetric and **0.736** for non-centrosymmetric space

<sup>\*</sup> E-mail: cini@unisi.it

t **4-Hydroxy-2-methyl-N-(2-pyridyl)-2H- 1,2-benzothiazine-3-carbox**amide **1.1** -dioxide.

groups) were performed through Patterson and Fourier methods. Two independent complex molecules are present in the asymmetric unit. The Pt, **CI, S,** 0, N and C atoms were treated anisotropically, the H atoms isotropically. The fullmatrix least-squares cycles converged to  $R = 0.0458$  and  $R' =$ 0.0477. Atoms H(16a), H(17a) and H(17b) were located through the Fourier-difference synthesis whereas all the other H atoms were set in calculated positions. The scattering factors were those of SHELX 76<sup>6</sup> and SHELXS 86<sup>7</sup> and of ref. 8. The isotropic thermal parameters for  $H(17a)$  and  $H(17b)$  and the **H(** 16a) proton were fixed at 0.08 and 0.06 **A2,** respectively. The





atomic coordinates are listed in Table 2. All the calculations were carried out on VAX 6610 and **IBM** 3090 machines using SHELXS<sup>6,7</sup> and PARST<sup>9</sup> computer packages.

Complete atomic coordinates, thermal parameters, and bond lengths and angles have been deposited at the Cambridge Crystallographic Data Centre; see Instructions for Authors, *J. Chem. SOC., Dalton Trans.,* 1996, Issue **1.** 

### **Infrared spectroscopy**

The IR spectra were recorded *uia* the KBr pellet technique on an FT-IR Perkin-Elmer model 1600 spectrometer.

#### **Molecular orbital calculations**

Extended-Huckel (EH) type molecular-orbital calculations were carried out using the ICONC&INPUTC package  $10$ implemented on a VAX 6610 computer. The parameters used were those standard in the program. The distance-dependent weighted Wolfsberg-Helmholz formula<sup>10,11</sup> was applied. In order to simplify the analysis, the molecule *trans-*   $[PtCl<sub>2</sub>(H<sub>2</sub>SO)<sub>{NC</sub><sub>5</sub>H<sub>4</sub>(NHCOH)-2]$  (Scheme 2) was studied



**Scheme 2** Representation of the molecule  $trans$ - $[PtCl_2(H_2SO)$ - ${NC<sub>s</sub>H<sub>4</sub>(NHCOH)-2}$  showing the coordinate system used





\* The H( 16b) atom was set in its calculated position.

**Table 3** Selected bond distances  $(A)$  and angles  $(°)$  for *trans*- $[PtCl_2(dmso)(HL)]$ 



\* The H( l6b) atom was set in its calculated position.



**Fig. 1** One of the two complex molecules found in the asymmetric unit of the crystals of *trans*-[PtCl<sub>2</sub>(dmso)(HL)]. The ellipsoids of the nonhydrogen atoms enclose 50% probability

in place of trans- $[PtCl<sub>2</sub>(dmso)(HL)]$ . The model molecule was constructed from the piroxicam complex using the molecular graphics package MacroModel<sup>12</sup> (graphics output: obtained *via* an Evans & Sutherland PS390 machine). Its geometry was kept fixed for all the calculations.

# **Results and Discussion**

Selected bond lengths and angles are given in Table **3,** and a drawing of one of the two molecules of the asymmetric unit is in Fig. 1. All the corresponding bond lengths and angles for the two molecules are equal within three times the estimated standard deviations (e.s.d.s). Each platinum atom is linked to two *trans* chloride ions, to the N(1') atom from the pyridyl group and to the sulfur atom of a dmso molecule. The Pt-Cl, Pt-N and Pt-S bond distances average 2.294(3), 2.062(10) and  $2.217(3)$  Å, respectively, in agreement with the values usually found for platinum complexes. $4.13-19$  The geometry around the metal ion is almost square planar, the largest deviation from canonical values being the angle Cl(1b)-Pt-Cl(2b) [175.0(1)°]. The metal atom deviates by  $0.027(2)$  Å (average) from the plane of the four donors. It is noteworthy that this deviation is towards the H(16) atom in both molecules. The distance of the H(16) atoms from the co-ordination planes is 2.1(1) **8,** (average), whereas the dihedral angle between the coordination plane and the  $N(2)C(3)[C(4)]C(14)[O(15)]N(16)$ - $\dot{C}(2')C(3')C(4')C(5')C(6')N(1')$  chain (see Scheme 1 and Fig. 1)

of the HL ligand is  $99.2(1)$  and  $94.9(1)$ ° for the two molecules, respectively. The  $Cl(2a)-Pt(1)-N(1'a)-C(2'a)$  and  $Cl(2b)-$ Pt(2)-N(1'b)-C(2'b) torsional angles are  $-78(1)$  and  $81(1)^\circ$ , respectively.

The H( 16) atoms of both molecules have a short contact with the metal centre (average 2.35 A; sum of the van der Waals radii 2.6-2.9 Å<sup>20</sup>). The N(16)-H(16) and the N(1)-Pt vectors are nearly parallel, the angles between the two lines being *8(5)* and  $16(1)$ <sup>o</sup> for molecule a and b, respectively. All these observations are evidence in favour of some  $Pt \cdots HN$  linking interaction. The mean values of the  $Pt \cdots H-N$  [121(3)°],  $N(16)-C(2')-N(1')$  [114(1)<sup>o</sup>] and  $N(16)-C(2')-C(3')$  [126(1)<sup>o</sup>] angles are consistent with the  $Pt \cdots HN$  linkage. The Pt-N( $1'$ )-C( $2'$ ), Pt-N( $1'$ )-C( $6'$ ), and N( $1'$ )-Pt-S(d) angles average 124.1(7), 116.6(7), 182.0(3)<sup>o</sup> (on the side of N-H), respectively, in agreement with some crowding of the  $N(2)[C(13)]SO_2$  portion of HL and the Cl<sup>-</sup> ligands [e.g.  $Cl(12) \cdots H(133)$  3.01(2) Å; sum of van der Waals radii, 2.9-H(16)-N(16)-C(2') [114(3)°], H(16)-N(16)-C(14) [118(1)°],  $3.3 \text{ Å}^{20}$ ].

It should be noted that the 360" rotation of the HL molecule around the  $Pt-N(1')$  bond is not free because of the repulsive forces between some atoms of HL and the  $Cl^-$  ligands. For a  $Cl(2)-Pt-N(1')-C(2')$  angle  $(\gamma)$  equal 0 (the co-ordination square and the pyridyl ring almost coplanar) there are very short intramolecular contacts. In the case that all the bond lengths and angles are fixed at the values found in the solid-state structure, the N(16)  $\cdots$  Cl(2) and C(6')  $\cdots$  Cl(1) intramolecular distances are 2.05(2) and 2.77(2) Å, respectively, much below the sum of the van der Waals radii (3.2-3.4 and 3.3-3.6  $\AA$ ,<sup>20</sup> respectively). The trend of the  $N(16) \cdots Cl(2)$  distance and of the N(16)-H(16) $\cdots$  Cl(2) angle as a function of  $\chi$  is shown in Fig. 2. It is evident that a  $\chi$  value of about  $-50^{\circ}$  should provide a significant  $N(16) \cdots C(2)$  intramolecular hydrogen bond  $[d(N \cdots C]) = 2.90 \text{ Å}, \text{angle } 110^{\circ}\text{J}.$  The N(16)  $\cdots$  Cl(2) distance of 3.61(1) Å and the N(16)-H(16) $\cdots$ Cl(2) angle of 110(2)<sup>o</sup> found in molecule a indicate that the  $N(16)-H \cdots Cl(2)$ interaction is, at best, very weak. This shows again that the  $Pt \cdots H-N$  linking interaction is operative. The existence of an M.  $\cdots$  H-N (M = Pt<sup>5,21-24</sup> or Pd<sup>21,23,25</sup>) interaction has recently been a matter of investigation and debate. The interest arises because  $M \cdots H-N/C$  interactions can cause  $H-N/C$ activation and because the linkage can influence the stability and reactivity of the metal complexes.<sup>24</sup>

The piroxicam molecule in the present complex is neutral, protonated at  $O(17)$  and has a 4,16-EZE conformation as that found in the solid-state structure of free piroxicam.26 A recent molecular mechanics analysis showed that the *ZZZ* conformation is more stable [by  $ca$ . 3 kcal mol<sup>-1</sup> (ca. 12.5 kJ mol<sup>-1</sup>)] than the  $EZE$  one;<sup>3</sup> the N(16)-H $\cdots$ O(17) hydrogen bond being one of the leading effects which favour *ZZZ.* Packing forces such as intermolecular hydrogen bonds and van der Waals interactions can explain the preference for *EZE* in the solid state. The existence of the  $Pt \cdots HN$  interaction in the present structure obviously favours the *EZE* conformation.

**A** comparison of the geometrical parameters of the piroxicam moieties of known structures shows that those of the  $C(14)/C(10)$  portion in *trans*-[PtCl<sub>2</sub>(dmso)(HL)] are very similar to those found for neutral free piroxicam, in agreement with the same protonation status and the same general EZE conformation. Some differences are found in the  $C(14)/N(1')$ fragment as a consequence of the metal co-ordination to  $N(1')$ . For instance the C(14)–N(16) bond length [1.394(17) Å] of this  $platinum(n)$  complex is closer to the relevant value of the zwitterionic form [1.385(6)  $A^{27}$ ] than to that of the neutral [1.353(4)  $\AA^{26}$ ] or of the anionic [1.365(4)  $\AA^{28}$ ] molecules. However, it is interesting that the N(16)–C(2')–N(1') bond angle is much the same in the platinum complex and in the free HL molecule, even though the sum of the van der Waals radii for Pt and N(16)  $(3.2-3.4 \text{ Å})$  is higher than the



**Fig. 2** Values of the  $N(16) \cdots C(2)$  intramolecular distance (d) and of the N(16)-H $\cdots$ Cl(2) angle ( $\alpha$ ) plotted against the Cl(2)-Pt-N( $1'$ )-C( $2'$ a) ( $\chi$ ) torsional angle for *trans*-[PtCl<sub>2</sub>(dmso)(HL)]. The values were obtained using MacroModel<sup>12</sup> by keeping fixed all the bond distances and angles



**Fig. 3** View of the molecular packing along the crystallographic *a* axis

Pt  $\cdots$  N(16) contact distance (3.10 Å). This is one more observation consistent with a  $Pt \cdots HN$  attractive interaction.

The *E* conformation of the 4,14 chain of the HL ligand is stabilized by an intramolecular  $O(17)$ -H  $\cdots$  O(15) hydrogen bond  $[d(O \cdots O) = 2.58(1)$  and 2.60(1) Å; angles 129(11) and  $140(11)$ <sup>o</sup> for the two molecules, respectively]. Furthermore, two weak intermolecular hydrogen bonds involve the  $H(17)$ atoms: namely O(17a)-H $\cdots$ O(15b)  $(x, y - 1, z)$  and O(17b)- $H \cdots$  O(15a)  $(x, y + 1, z) [d(\theta \cdots \theta)] = 3.15(1)$  and 3.38(1) Å; angles 105(8) and 113(9)° for the two molecules, respectively]. No stacking interaction involving the pyridyl or the  $C(5)$ /  $C(10)$  rings could be revealed (Fig. 3). There are no Pt $\cdots$ Pt contacts below 4 A.

#### **Infrared spectroscopy**

The  $Pt \cdots H-N$  interaction is also identifiable through infrared spectroscopy in the solid state (Fig. 4). The  $v(N-H)$  band is at  $3250 \text{ cm}^{-1}$ , some 90 cm<sup>-1</sup> lower than that of free HL (3340 cm<sup>-1</sup>). It also broadens upon co-ordination. Similar effects were found for *trans*-[PtCl<sub>2</sub>{ $o$ -Ph<sub>2</sub>PC<sub>6</sub>H<sub>4</sub>NHC(O)Ph}<sub>2</sub>],<sup>29</sup> *cis*-[Pt-Me,<sup>21</sup> and for  $[Ni(CO)\{NH(C_2H_4PPh_2-2)_3\}]^{+30}$  where a  $Pt \cdots HN$  interaction was considered present.  ${o-Ph_2PC_6H_4NC(O)C_6H_4}\{o-Ph_2PC_6H_4NHC(O)Ph\}~_2C_6H_5$ -

#### **EHMO calculations**

The frontier orbitals do not have significant Pt, N(16) and H( 16) atomic orbital character. One molecular orbital (MO), with high  $p_z(Pt)$ ,  $p_y[N(16)]$  and s[H(16)] character, lies some 1140 **kJ** mol-' above the highest occupied molecular orbital

**Table 4** Selected molecular orbitals (decreasing energies) for the model molecule **trans-[PtC1,(H,SO){NC5H,(NHCOH)-2)]** [only those with some N( 16) and Pt character are reported]. Coefficients of atomic orbitals higher than 0.15 are reported. The HOMO and the lowest unoccupied molecular orbital (LUMO) are given for comparison. The coordinate system is that in Scheme 2

	Coefficients of the atomic orbitals				
<b>MO</b>					$E/eV^*$
22	$0.30p_v$ Pt	$0.66p$ , Pt	$-0.27p$ , Cl(1)	$-0.29p$ , Cl(2)	0.94
	0.28p, S	$0.27s$ O(d)	0.22p, O(d)	$-0.18p$ , N(1')	
	$-0.56p$ <sub>v</sub> N(16)	$0.16p_z N(16)$	$-0.31p_y C(2')$	$-0.18p_zC(2')$	
	$-0.20p_vC(3')$	$-0.16p_z C(4')$	$-0.23pz C(6')$	0.37s H(16)	
27(LUMO)	$0.15d_{xy}$ Pt	0.55p, N(1')	$-0.19p_{r}C(2')$	$-0.42p_rC(3')$	$-8.71$
	0.59p, C(4')	$-0.55p_xC(6')$			
28(HOMO)	$-0.84d_{xy}$ Pt	$0.27d_{yz}$ Pt	$0.39p_v Cl(1)$	$-0.41 p_v Cl(2)$	$-10.84$
31	$-0.15d_{2}$ Pt	$-0.23d_{v}$ . Pt	0.22p, O(15)	$-0.57p_v O(15)$	$-12.14$
	$-0.67p$ , O(15)	$-0.23p$ , N(16)			
42	$-0.18d_{ur}$ Pt	$-0.34p_v Cl(1)$	0.19p. Cl(1)	$-0.41 p_v Cl(2)$	$-14.65$
	$0.23d$ , $Cl(2)$	$-0.19p_v S$	0.25p, O(d)	$0.17p_v N(16)$	
	$-0.18p_vC(2')$	$0.21p_vC(3')$	$-0.17p_r C(4')$	$-0.17pv C(6')$	
43	$0.23d_{yy}$ Pt	$0.38p_v Cl(1)$	$-0.25p_v$ Cl(2)	$-0.23p_r O(15)$	$-14.78$
	$0.19p$ , N(1')	$-0.31p$ , N(16)	$0.23p_rC(4')$	$-0.28p$ , C(14)	
45	$0.22d_{\text{av}}$ Pt	$-0.23d_{1}$ . Pt	$0.20p_r Cl(1)$	$0.40 p_v Cl(1)$	$-15.08$
	$0.38p$ , Cl(2)	$0.18p_x O(15)$	$0.38p_r N(16)$		
47	$0.27d_{xy}$ Pt	$0.36d_{xz}$ Pt	$0.25p_v Cl(1)$	$0.43p_z$ Cl(1)	$-15.18$
	$-0.37p_v$ Cl(2)	$-0.40p, Cl(2)$	$0.16p_x N(16)$		

\* eV  $\approx 1.60 \times 10^{-19}$  J.



**Fig. 4** Infrared spectra (KBr pellets), in the 4000–2500 cm<sup>-1</sup> region of  $(a)$  HL and  $'b)$  *trans*-[PtCl<sub>2</sub>(dmso)(HL)]

(HOMO) (Table 4, number 22). However, various occupied MOs with some metal  $(d_{z^2}, d_{xy}, d_{xz}$  and  $d_{yz}$ ),  $p_z[N(16)]$ ,  $p_y[O(15)]$  and  $p_z[O(15)]$ , without any appreciable H(16) character were computed for the trans- $[PtCl<sub>2</sub>(H<sub>2</sub>SO)<sub>3</sub>(NC<sub>5</sub> H_4(NHCOH)-2$ ] model system (numbers 31, 42, 43, 45 and 47). Among the latter, that (31) closer to the frontier region is 130 kJ mol<sup>-1</sup> more stable than the HOMO and has  $d_{z^2}(Pt)$ ,  $d_{vz}$ (Pt) and  $p_z$ [N(16)] character.

The calculated atomic charges of the Pt and **H(** 16) atoms are  $-0.32$  and  $+0.18$  respectively. This suggests that electrostatic forces can play a significant role in the Pt  $\cdots$  H(16) interaction, in agreement with previously reported investigations.<sup>22,30</sup>

In conclusion a new metal complex of piroxicam is presented. Its crystal and molecular structure shows that the pyridyl nitrogen is the preferred donor, instead of the hydroxy and amide oxygen and benzothiazine nitrogen atom. This study reveals also that the drug molecule can adopt the *EZE*  conformation when complexed, in addition to the *ZZZ* one previously found for copper $(n)$  and cadmium $(n)$  complexes.<sup>2</sup> Finally this work adds a new example to the scanty batch of compounds for which the  $Pt \cdots H-N$  interaction was noted and reported. Some electron density from the metal centre (at least *via*  $d_{z^2}$  and  $d_{vz}$ ) is possibly passed to the NH function which exhibits a bond weakening (IR spectrum, Fig. 4). An electrostatic  $Pt \cdots H$  attraction then enforces the affinity of the metal centre towards the NH group.

Work is planned in this laboratory to investigate the reactivity of the complex, particularly with nucleobases, nucleotides and nucleic acids, and to perform appropriate tests for anti-inflammatory activity.

### **Acknowledgements**

**<sup>I</sup>**thank MURST (Minister0 dell'Universita e della Ricerca Scientifica e Tecnologica, Roma) for financial support, and Pfizer Italia (Roma) for the gift of piroxicam.

#### **References**

- **<sup>1</sup>**N. Farrel, D. M. Kiley, **W.** Schmidt and M. P. Hacker, *Inorg. Chem.,*  1990,29,397; **M.** van Beusichem and N. Farrel, *Inorg. Chem.,* 1992, 31, 634.
- 2 R. Cini, G. Giorgi, A. Cinquantini, C. Rossi and M. Sabat, *Inorg. Chem.,* 1990,29,5197.
- *3* R. Cini, R. Pogni, R. Basosi, A. Donati, C. Rossi, **L.** Sabadini, **S.** Lorenzini, L. Rollo, R. Gelli and R. Marcolongo, *Metal Based Drugs,* 1995, 2,43.
- 4 R. Cini, F. P. Fanizzi, F. P. Intini, L. Maresca and G. Natile, *J. Am. Chem. SOC.,* 1993,115, 5123.
- 5 A. Albinati, F. Lianza, P. **S.** Pregosin and B. Muller, *Inorg. Chem.,*  1994,33,2522.
- 6 G. M. Sheldrick, SHELX 76, Program for Crystal Structure Determination, University of Cambridge, 1976.
- 7 G. M. Sheldrick, SHELXS 86, Program for Crystal Structure Determination, University of Göttingen, 1986.
- 8 *Iriternational Tables of' X-Ray Crystallography.* Kynoch Press, Birmingham, 1974, vol. 4.
- 9 M. Nardelli, PARST, A System of Computer Routines for Calculating Molecular Parameters from Results of Crystal Structure Analyses, *Comput. Chem.,* 1983,7,95.
- 10 G. Calzaferri and M. Brandle, ICONC&INPUTC, University of Berne, QCPE program no. QCMP **116,** 1992.
- 11 G. Calzaferri, L. Forss and I. Kamber, *J. Phys. Chem.,* 1989, 93, 5366; G. Calzaferri and R. Hoffmann, *J. Chem. Soc., Dalton Trans.,*  1991,917.
- 12 **W.** C. Still, F. Mohammadi, N. **G.** J. Richards, **W.** C. Guida, M. Lipton, G. Chang, T. Hendrickson, F. DeGunst and **W.** Hasel, MacroModel V3.0, Department of Chemistry, Columbia University, New York, 1990.
- 13 B. Voissat, N.-H. Dung, N. Rodier and F. Bentfrit, *Acta Crystallogr., Sect. C,* 1995, **51,** 878.
- 14 R. Cini, P. A. Caputo, **F.** P. Intini and **G.** Natile, *Inorg. Chem.,* 1995,

34, 1130; R. Cini, F. P. Intini, G. Natile and C. Pacifico, *J. Chem.*  Soc., *Dalton Trans.,* 1994, 3753.

- I5 R. E. Cramer and M. J. J. Carrie, *Inorg. Chem.,* 1993, 32, 3509.
- 16 G. Natile, F. P. Fanizzi, L. Maresca, **A.** M. Manotti-Lanfredi and **A.** Tiripicchio, *J. Chrvn. Soc., Dalton Truns.,* 1985, 1057.
- I7 J. **F.** Vollano, **E.** E. Blatter and J. C. Drabowiak, *J. Am. Chem. Suc.,*  1984,106,2732.
- 18 G. Muller, J. Riede, R. Beyerle-Pfniir and B. Lippert, *J. Am. Chem. Soc.,* 1984, 106, 7999.
- 19 R. Koruda, **S.** Niedle, I. M. Ismail and P. J. Sadler, *Inorg. Chem.,*  1983,22,3620.
- 20 **A.** Bondi, *J. Phys. Chem.,* 1964, 68,441.
- 21 D. Hedden, D. M. Roundhill, W. C. Fultz and **A. L.** Rheingold, *Organometallics,* 1986, *5,* 336.
- 22 L. Brammer, J. M. Chernock, P. L. Goggin, R. J. Goodfellow and **A.** J. Orpen, *J. Chem. Soc., Dalton Trans..* 1991, 1789.
- 23 **I.** C. M. Wehman-Ooyevaar, D. M. Grove, P. de Vaal, **A.** Dedieu and G. van Koten, *Inorg. ('hem.,* 1992,31, 5484.
- 24 I. C. M. Wehman-Ooyevaar, D. M. Grove, **H.** Kooijman, P. van der Sluis, **A. L.** Spek and G. van Koten, *J. Am. Chem. Soc.,* 1992, **114,**  9916.
- 25 **A.** J. Blake, **A.** J. Holder, **Y. V.** Roberts and M. Schroder, *J. Chem. Soc., Chem. Commun.,* 1993,260.
- 26 B. KojiC-Prodik and Z. Ru2ik-ToroS, *Acta Crystallogr., Sect. B,* 1982, 38, 2948.
- 27 J. Bordner, J. **A.** Richards, **P.** Weeks and **E.** B. Whipple, *Acta Crystallogr., Sect. C,* 1984,40, 989.
- 28 J. Bordner, P. D. Hammen and **E. B.** Whipple, *J. Am. Chem.* Soc., 1989,111,6572.
- 29 D. Hedden and D. M. Roundhill, *Inorg. Chem.,* 1985,24,4152.
- 30 F. Cecconi, C. **A.** Ghilardi, P. Innocenti, C. Mealli, **S.** Midollini and **A.** Orlandini, *Inorg. Chem.,* 1984,23,922.

*Received 6th July 1995; Paper 5/04392A*